Experimental drug may stop stem cell growth in patients with breast cancer.
The Houston Chronicle (12/12, Finley) reported that, according to research reported at the San Antonio Breast Cancer Symposium, researchers "have an experimental drug that seems to stop" stem cells "in breast cancers." For the study, the researchers "first identified a vulnerable target on the breast stem cells called the Notch receptor and used an experimental drug, gamma-secretase inhibitor, along with a common anticancer drug, docetaxel -- first on mice grafted with human tumors, and later in a few women with advanced breast cancer."
MedPage Today (12/12, Phend) reported that "compared with baseline biopsies, those taken at the end of treatment had significantly fewer cancer stem cells measured by CD44/CD24 expression." But, "tumor regression wasn't seen immediately with Notch inhibition," which the researchers said "likely reflects daughter cells dying off from chemotherapy with progressively fewer stem cells to repopulate them."
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου